Explores targeted protein degradation using cyanobenzothiazoles, indicating new therapeutic possibilities.
and HER2 without hook effects, outperforming clinical inhibitors. This work provides the first proteome-wide map of ligandable NCys residues and establishes CBT as a versatile platform for covalent targeted protein degradation (TPD), opening new avenues for precision therapeutics.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: